Adaptive Biotechnologies Corporation (ADPT) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−246.8x

Market Cap

$3.87B

MomentumView details →

1D Return

−1.41%

YTD Return

−62.87%

RSI (14)

33.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−246.8x

Market Cap

$3.87B

RSI (14)

33.5

MomentumView details →

1D Return

−1.41%

YTD Return

−62.87%

SummaryUpdated Jun 1, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is a commercial-stage biotechnology company founded in 2009 and headquartered in Seattle, Washington. The company was originally incorporated as Adaptive TCR Corporation before changing its name in December 2011. Adaptive went public in June 2019 and has since established itself as a leader in immune medicine platform development. The company focuses on leveraging the adaptive immune system to develop diagnostic tests and therapeutic treatments for various diseases including cancer, autoimmune conditions, and infectious diseases.

Ask drillr about Adaptive Biotechnologies Corporation →

ProfitabilityView details →

Gross Margin

75.44%

Net Margin

−20.73%

EBITDA Margin

−5.18%

ROE (TTM)

−44.68%

ROA (TTM)

−9.97%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

+50.13%

EPS YoY

+50.32%

FCF YoY

+70.98%

Revenue CAGR 3Y

+14.34%

EPS CAGR 3Y

+63.89%

EBITDA YoY

+83.82%

EarningsView details →

EPS (Actual)

−$0.25

EPS Surprise

−87.11%

Beats (12Q)

8/12

Next Q EPS Est

−$0.10

Avg Surprise (4Q)

−2.37%

Rev Surprise

9.35%

Capital & dividendView details →

Debt/Equity

2.87x

Current Ratio

4.79x

Quick Ratio

4.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

308.08M

Net Income (TTM)

−63.85M

Op. CF (TTM)

−21.01M

Next earningsNov 4, 2026 →

Latest newsMore news →

Harlan Robins, co-founder of Adaptive Biotechnologies, raised $15 million for a new startup focused on rethinking how AI trains on scientific data.18d ago

Adaptive Biotechnologies announced the planned separation of its Immune Medicine business to become a pure-play MRD diagnostics company.35d ago

Similar companies

Catalyst Pharmaceuticals, Inc.CPRX IDEAYA Biosciences, Inc.IDYA Amylyx Pharmaceuticals, Inc.AMLX Tango Therapeutics, Inc.TNGX Shanghai Haohai Biological Technology Co., Ltd.06826.HK Arcus Biosciences, Inc.RCUS Find similar companies →

Latest newsMore news →

Harlan Robins, co-founder of Adaptive Biotechnologies, raised $15 million for a new startup focused on rethinking how AI trains on scientific data.18d ago Adaptive Biotechnologies announced the planned separation of its Immune Medicine business to become a pure-play MRD diagnostics company.35d ago Adaptive Biotechnologies reported financial results for the second quarter of 2026.37d ago